Loading
A phase 1/2 trial of NP-G2-044 Monotherapy in advanced solid tumours, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05023486 by Novita Pharmaceuticals, Inc., with 121 participants enrolled, started 2021-12-07 and due to reach its primary completion in 2026-06-30. Interventions recorded: NP-G2-044 Monotherapy, Anti-PD-1 Therapy and NP-G2-044 Combination therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/